|
|
| November 15, 2011: Dr. Stephen Nicholls and Dr. Dylan Steen discuss: Lipid-modulating effects of evacetrapib, a novel CETP inhibitor, admin |
Lipid-modulating effects of evacetrapib, a novel CETP inhibitor, administered as
monotherapy or in combination with the most commonly used statins
Research support: AstraZeneca, Anthera, Eli Lilly, Novartis, Resverlogix, Roche and
LipoScience
Consulting and honoraria: AstraZeneca, Eli Lilly, Anthera, Omthera, Merck, Takeda,
Resverlogix, Sanofi-Aventis, CSL Behring, Esperion, Boehringer Ingelheim
The study was sponsored by Eli Lilly
[ Download video ] |
|
No comments have been submitted
|